GSK's Sandy Macrae On R&D For Emerging Markets: An Interview With PharmAsia News (Part 1 Of 2)
This article was originally published in The Pink Sheet Daily
GSK's Senior VP Asia Pacific, Japan, and Emerging Markets R&D has been busy pitching the company's established presence in emerging markets to companies looking to expand beyond traditional markets, and even some that aren't.
You may also be interested in...
NICE considers denosumab a cost-effective use of NHS resources for second-line osteoporosis use.
MUMBAI - India's Dr. Reddy's Laboratories and pharmaceutical major GlaxoSmithKline are in active discussions to partner on marketing a uniquely designed combination drug that can combat cardiovascular and cerebrovascular diseases and will be priced "very economically.
SINGAPORE - GSK APJEM R&D is pretty hefty as far as acronyms go, but GlaxoSmithKline's Judith Hills wants to make sure observers do not over look the research and development title in the new GSK division